There are concerns over the safety of this practice as rat studies demonstrated a high malignant transformation rate. As yet, there are no clinical reports of cidofovir-induced malignant changes in humans. Methods: Telomerase immortalised human keratinocytes (hTert) stably expressing E6 proteins from either low-risk HPV6b or high-risk HPV16 and vector control cells were treated with either low-dose (5 µg/ml) or higher dose (30 µg/ml) cidofovir for 2 days and the effects evaluated by clonogenic survival assays. Based on these results, gene expression microarray analysis was performed on cidofovirtreated low-risk E6 and vector cells before, during and after drug treatment, and the results verified by real-time PCR.
Introduction
whereby human papillomavirus (HPV)-induced papillomas grow within the larynx and trachea to cause airway compromise. Without periodic surgical removal of these lesions asphyxiation can result. Furthermore, there is also a risk of malignant transformation in the paediatric group (<1%) [7] .
Studies in rats have clearly demonstrated that cidofovir can cause adenocarcinoma [8] , although there are no reports of cidofovir-induced malignancies in humans. There is convincing evidence that cidofovir is effective against high-risk HPV-related disease [9, 10] ; however, understandably, there is some anxiety about the use of this drug to treat benign low-risk HPV-related disease in children. There is only one in vitro study that compares cidofovir treatment of low-versus high-risk HPV oncogene-expressing cell lines, which indicated that low-risk E6-expressing cells were growth-inhibited less than high-risk E6 cell lines [2] . The cell lines used in that study were human C33A cervical carcinoma cells and although comparisons were made against a common isogenic background, a non-malignant cell would have been preferable.
A crucial aspect of the function of cidofovir is that is it preferentially incorporated by viral rather than by human DNA polymerase [11, 12] , which explains why it is effective against CMV, as this virus encodes a specific DNA polymerase. However, HPV hijacks the host DNA polymerase; therefore, the effect of cidofovir is not related to polymerase specificity as it is for CMV. Thus, the response of HPV-infected cells to cidofovir is probably related to the established ability of this virus to negatively influence the DNA repair capacity of cells [13, 14] . These studies describe the effects of high-risk HPV on DNA repair processes, yet it is known that low-risk virus can also compromise the function of p53, albeit not to the same extent as high-risk virus [15] . The combination of a genotoxic drug, such as cidofovir, with virally-induced diminished DNA repair capacity [16] will undoubtedly promote the accumulation of genetic damage. In light of these observations, we feel that caution should be exercised when treating what is essentially a benign low-risk HPV related lesion with cidofovir. Clearly more research is urgently needed concerning the potential long-term risks of this off-license use of cidofovir.
Experimentally, it would be desirable to obtain consecutive biopsies from cidofovir-treated RRP lesions taken over a relatively short period of time. However, it is not ethical to subject patients to this practice. As an alternative, we now report the effects of cidofovir on clonogenic survival and gene expression of nontransformed human keratinocytes that express the HPV6b E6 oncoprotein or vehicle control.
Methods

Cell culture
Telomerase immortalised human keratinocytes (hTert) were cultured in keratinocyte-SFM (GIBCO, Paisley, UK), 0.3 M calcium chloride, epidermal growth factor, 12.5 mg bovine pituitary extract and 5 ml penicillinstreptomycin solution (10,000 units penicillin and 100 mg streptomycin; Sigma-Aldrich Co., St Louis, MO, USA). Cells were maintained in a monolayer culture at 37ºC in a 5% CO 2 atmosphere. The establishment of HPV16 E6-transfected hTert keratinocytes cells has been previously described [17] .
Plasmid constructs were generated by ligating the open reading frames of HPV6b E6 (accession number NC_001355) and HPV16 E6 (accession number NC_001526) into pcDNA 3.1 (eukaryotic expression vector; Invitrogen Ltd, Paisley, UK) and transformed through Escherichia coli XL1 Blue expansion with ampicillin selection. The plasmid sequence was verified using a Cells-to-cDNA™ II kit (Ambion, Cambridgeshire, UK) to generate complementary DNA (cDNA) from cellular messenger RNA (mRNA). Standard real-time PCR was used with E6-specific primers. The plasmid was lipofected into hTert keratinocytes using lipofectamine and G418 selection (GIBCO). Both polyclonal and monoclonal cell lines were derived from E6-and vector-transfected cells.
Clonogenic assay
Clonogenic assays were employed in the evaluation of the effect of cidofovir upon the hTert keratinocyte cell system (vector, T6E6 and T16E6 cell lines). Following an initial evaluation of drug potency by means of cidofovir kill curves, AQ96 cell proliferation analysis and flow cytometry, the hTert cell lines were exposed to cidofovir at low (5 µg/ml) and high (30 µg/ml) dose for 2 or 4 days. Cells were harvested and serially diluted to give 3,000, 1,000, 333, 111, 33, 11, 3 and 1 cells plated in triplicate per well in 96-well plates. These were evaluated on a daily basis during a 7-day incubation period following the initial 2 days exposure to drug. Estimation of surviving viable cell numbers was performed using CellTiter 96 ® AQueous One Solution ® (Promega, Southampton, Hampshire, UK) according to the manufacturer's instructions and toluidine blue staining was also performed for a visual appreciation of surviving viable cell colonies.
Gene microarray analysis evaluating the effects of low-dose cidofovir on gene expression of the hTert E6 cells
Affymetrix GeneChip
® human genome U133 plus 2.0 arrays (Affymetrix UK Ltd, High Wycombe, UK) were used to assess the effects of cidofovir exposure on E6-transfected and control hTert cells. Two untreated cultures of each cell line (hTert vector, hTert T6E6 and hTert T16E6) were seeded at equal densities and grown until 50% confluent. These were harvested for RNA using the Trizol ® (Invitrogen Ltd) extraction method. Duplicate cultures from each cell line were inoculated at a range of densities and treated with 5 ug/ml cidofovir for 2 days. Flasks seeded at the appropriate density, estimated to achieve 50% confluence following 2-day exposure to drug were harvested directly for RNA. The medium was changed on the remaining cultures and incubated for a series of consecutive 'chase' periods until cultures seeded at an appropriate density achieved 50% confluence whereupon these were also harvested for RNA. In this way, potential artefacts caused by differences in cell density were minimized. RNA integrity was assessed using an Agilent 2100 Bioanalyser (Agilent Technologies, West Lothian, UK) and 5 µg of RNA prepared and hybridized to the arrays according to the manufacturer's protocol. GeneChip ® array raw CEL data were analysed using the R and Bioconductor software limma statistical package. The differential expression between each comparative set (for example, E6 versus vector, E6 no treatment versus E6 plus treatment) was summarized and ranked according to fold change.
Real-time quantitative PCR
Genomic DNA was removed from the RNA using the DNA Free Kit (Ambion Europe Ltd, Cambridgeshire, UK). RNA (1 µg) was reverse transcribed using SuperScript II TM RNase H reverse transcriptase and oligo (dT) [12] [13] [14] [15] [16] [17] [18] (Invitrogen Ltd) following the manufacturer's guidelines. The Human Universal ProbeLibrary Set (Roche, West Sussex, UK) employing proprietary locked nucleic acid analogues was used for real-time quantitative PCR to measure expression levels in genes of interest. Using the Roche Online Assay Design Centre, specific primers and an associated probe were designed for each transcript (Table 1 ). To allow for accurate comparison and to compensate for variations in cell number, RNA isolation, reverse transcription and PCR amplification efficiency, two endogenous house-keeping transcripts were chosen using the geNORM algorithm [18] . Briefly, the cell lines were screened for eight reference genes (GAPDH, B2M, ACTB, RPL32, RPL13A, HPRT1, HMBS and SDHA). The algorithm calculates the stability of each transcript and sequentially removes the least stable transcript until the two most stable transcripts remain, these being ACTB and RPL32.
cDNA was diluted 1 in 40. Each 10 µl reaction comprised 4 µl diluted cDNA, 5 µl 2×LC480 Probe Master (Roche), 0.1 µl each primer (20 µM; Metabion, PlaneggMartinsried, Germany), 0.1 µl probe (10 µM; Human Universal ProbeLibrary Set) , and 0.7 µl of water. Samples were then amplified on a Roche LightCycler ® 480, and the temperature programme was 95°C for 5 min followed by 50 cycles of 95°C for 10 s and 60°C for 30 s. Real-time PCR was performed in triplicate with negative controls for each assay. The amounts of target genes expressed in a sample were normalized to the average of the two endogenous controls.
Statistical analyses
Data from clonogenic studies were analysed by paired Student's t-tests using Microsoft Excel Software and attributing a P-value of 0.05 as significant. The reproducibility of real-time reverse transcriptase PCR was expressed as a coefficient of variation (CV), which was calculated as the percentage of the sd divided by the cycle threshold value mean.
Results
Low-dose cidofovir increases the long-term cell survival of E6-expressing cells
Clonogenic assays show no difference in 7-day post-treatment survival for cidofovir-treated versus untreated control vector hTert cells. However, exposure of hTert T6E6 cells to 5 µg/ml of cidofovir for 2 days showed a significant increase in the 7-day survival of drug-treated cells above that of untreated control cells, which was also observed in hTertT16E6 cells ( Figure 1 ). Pooled data (six runs) for both lowrisk and high-risk E6-expressing cells show significantly improved long-term survival compared with vector control cells when exposed to 5 µg/ml cidofovir for 2 days, (hTert T6E6 P=0.0007, hTertT16E6 P=0.00023 and hTert vector control P=0.62; Figure 2 ).
None of the cell lines tested survived 2-day treatment with the higher dose of 30 µg/ml cidofovir. Because RRP is mainly caused by low-risk HPV, all subsequent gene expression analyses were carried out using the HPV6b E6-transfected hTert cells.
Cidofovir induces E6-specific alterations in gene expression
The observation that a 2-day treatment with low-dose cidofovir increased the long-term survival of low-risk and high-risk HPV E6-expressing hTert cells prompted us to investigate any changes in gene expression that were associated with this phenomenon. Thus, an experiment was designed to assess changes that might occur both when the drug is present and when it is withdrawn in order to mimic more closely the conditions used for the clonogenic assay. Comparison of gene microarray data initially showed that specific cohorts of genes were regulated differently in E6-containing cell lines when compared with vector control cells (see supplementary  Table 1 in Additional file 1). These results were further refined by analysing which genes underwent significant cidofovir-induced dysregulation in E6-expressing versus cidofovir-treated control cells. Only genes up-regulated by a minimum of twofold were included, as this arbitrary figure is adopted by other groups using gene microarray analysis. On the basis of analyses of the first 200 up-regulated genes, 29 were selected and assessed for known functional data. Some of the genes specifically altered by cidofovir in low-risk E6-expressing Confirmation of cidofovir-induced E6-specific alterations in gene expression by real-time PCR Figure 3) . Furthermore, all of these genes were up-regulated following the 2-day cidofovir treatment or during the chase period in vector cells ( Figure 4A ). When compared with untreated hTert E6 cells, AKAP13, CCGN2, EPPK1, HOPX, SCNN1G, SERPINB13, USP47 and ZNF294 were reduced to undetectable levels in cidofovir-treated E6 cells either after 2 days of drug treatment or following the chase period (Figure 4B ). When compared with 2-day cidofovir-treated vector cells, 2 days of drug treatment increased expression of BUB1, C6orf32, CTNNA1, ENC1, EPPK1, GJC1, HSP90AB1, IGF1R, IL1RL1, JPH2, RBM47, SLC16A7 and ZFP36L2 in hTert E6 cells ( Figure 5A ). When compared with cidofovir-treated vector cells harvested after the chase period, C6orf32, CCL5, CFB, IF127 and IL1Rl1 all showed marked up-regulation 96-Well plates were seeded in triplicate with 2,000, 1,000, 333, 111, 33, 11 serial dilution of cells, which had been previously exposed to either low-(5 µg/ml) or high-(30 µg/ml) dose cidofovir for 2 days. These were incubated for a further 7 days. Then, numbers of surviving viable cell were estimated by addition of CellTiter 96 ® AQueous One Solution ® (Promega, Southampton, Hampshire, UK) to each well (see Figure 2) . Finally, surviving cells were fixed and stained with toludine blue for a visual appreciation of surviving viable cell colonies. Results of this analysis are shown for starting cell densities of 1,000 and 333 low-dose cidofovir-treated cells. These data show that greater numbers of telomerase immortalised human keratinocyte (hTert) E6 cells survive low-dose cidofovir than untreated controls, whereas there was no difference between cidofovir-treated or -untreated hTert vector cells. High-dose cidofovir killed all cells equally, irrespective of cell type, and the data shown is representative of three separate experiments.
in drug-treated hTert E6 cells also harvested after the chase period ( Figure 5B) .
Out of the cidofovir-induced changes specific to E6 cells, the most important up-regulated oncogenes identified were RANTES (CCL5), IGFR1, SERPINB13, ZFP36L2 and ZNF294. Furthermore, the tumour suppressor HOPX was reduced to undetectable levels by cidofovir treatment of E6 cells.
Discussion
Clonogenic assays of cidofovir treatment
Clonogenic assays are used to evaluate long-term cell survival, as they test the ability of cells to generate progeny following exposure to a drug or treatment (radiation) that induces reproductive death as a result of cumulative damage to chromosomes and DNA [19] . In this communication, clonogenic assays were used to specifically test the long-term survival and proliferation of E6 or control vector-transfected hTert keratinocytes exposed to low-dose cidofovir.
Our data evidently shows that 2 days of treatment with low-dose cidofovir improves the survival and stimulates growth of cells that contain either low-or highrisk HPV E6; however, 4 days of drug treatment did not show this effect (data not shown). These observations indicate that the duration, dose and treatment intervals used with cidofovir might be of clinical importance as the half-life of the drug in vivo is only 2.5 h [20] . Indeed, it is consistent with our data showing that cidofovirtreated RRP lesions show rapid regrowth if the interval between treatments is too long [21] . Furthermore, when cidofovir is administered by direct injection into RRP lesions, it will presumably diffuse away from the treatment site and generate a drug concentration gradient. Thus, adjacent peripheral tissues will, at some point, contain cidofovir at levels that might facilitate the survival of HPV-infected cells and which might also produce HPV-related alterations in gene expression. This is an important consideration as it is known that a high proportion of the population might harbour dormant commensal HPV in nearby adenoidal and tonsillar tissue [22, 23] as well as in pharyngeal mucosa [24] . Optical density at 490 nm. For telomerase immortalised human keratinocyte (hTert) T6E6 cell lines, the absorbance measurement for a starting density of 1,000 cells is closer to that of hTert vector and hTert T16E6 cells with starting densities of 333 cells (that is, A is smaller than B). Downward arrows show starting numbers that were optimal for analysis across each of the three cells lines; thus, using the control absorbance level indicated by the horizontal line on the graph, a Student's t-test was performed to calculate the P-values for differences between cidofovir-treated and untreated control cells. The graph indicates statistically significant improved survival for both low-risk and high-risk E6-expressing cells initially exposed to low-dose cidofovir (P=0.0007 for hTert T6E6 and P=0.013 for hTert T16E6), whereas there was no difference between treated and untreated hTert vector cells (P=0.62). The data shown is representative of three separate experiments.
Analysis of HPV6b E6-and cidofovir-related changes in gene expression
Interpretation of this expression data are necessarily complex being dependent on the cell type and treatment chosen for baseline comparison and for this reason we will focus on what we consider to be the most significant cidofovir-induced changes that are specific to E6 cells.
Untreated E6 cells show a 1.7-fold increase in expression of the chemokine (C-C motif) ligand RANTES (CCL5) when compared with vector cells (Figure 3) . Treatment of vector cells with cidofovir for 2 days produced a modest 2.3-fold increase in CCL5, and E6 cells also show a small 1.3-fold increase with this treatment. However, CCL5 shows a marked 12.4-fold increase following the chase period, whereas no effect was seen in vector cells. Indeed, when this effect was normalised to cidofovir-treated chase vector cells, CCL5 increased by 21-fold in the equivalent E6 cells ( Figure 5B ). This is potentially an important change as CCL5 is thought to play a major role in the development of multiple cancers. For example, it is known to be transactivated by human T-cell leukaemia virus [25] and the Epstein-Barr virus transforming protein LMP1 [26] . Furthermore, CCL5 is up-regulated in a variety of malignancies (Table 2) and it has been speculated to play an important role in carcinogenesis in both breast and cervical cancer [27] . Interestingly, RANTES is also known to be a C-C chemokine that targets CD4 + T-cells [28] . The expression of RANTES is provoked by IGF1R [29] . IGF1R is a newly recognized self-antigen, the expression of which is affected by cidofovir in our work.
Expression of E6 reduces the expression of IGF1R fourfold ( Figure 3) ; however, 2 days of cidofovir treatment of these cells increases IGF1R by 110-fold and this remained increased 8-fold following the chase period ( Figure 4B ). Cidofovir also up-regulated IGF1R in Tert vector cells, but to a much lesser extent (Figure 4A) , and comparison of 2-day drug-treated E6 cells to the equivalent vector cells shows a 6.4-fold increase in IGF1R ( Figure 5B ). IGF1R is highly overexpressed in many malignant tissues [30] [31] [32] , where it functions as an anti-apoptotic agent enhancing cell survival. Furthermore, its overexpression is associated with increased aggression of tumours and a reduced requirement for growth factors. Inhibition of IGF1R expression induces apoptosis, decreases tumour growth and inhibits metastatic spread [33, 34] .
SERPINB13 expression is reduced 147-fold by expression of E6 (Figure 3) . Although down-regulated 4.4-fold in vector cells after 2 days of cidofovir treatment, it is up-regulated 5.6-fold in these cells following the chase period ( Figure 4A ). E6 cells, however, have undetectable SERPINB13 after 2 days of drug, CCL5  CFB  CROP  CTNNA1  ENC1  EPPK1  GJC1  HOPX  HSP90AB1   IF127  IGF1R  IL1RL1  JPH2  PDE4DIP  RBM47  SCNN1G  SERPINB13  SLC16A7  SRRM2  TAOK1  TPR  USP47  ZFP36L2 C6orf32  CCGN2  CCL5  CFB  CROP  CTNNA1  ENC1  EPPK1  GJC1  HOPX  HSP90AB1   IF127  IGF1R  IL1RL1  JPH2  PDE4DIP  RBM47  SCNN1G  SERPINB13  SLC16A7  SRRM2  TAOK1  TPR  USP47 ZFP36L2 ZNF294 
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increasing to 40-fold up-regulation following the chase period ( Figure 4B ). Comparing drug-treated vector to E6 cells shows that SERPINB13 is undetectable in E6 cells following 2 days of drug treatment and is still 20.8-fold reduced in these cells in the chase period. This result is important as loss of SERPINB13 expression is known to be associated with the development of head and neck squamous cell carcinomas and it has been shown to be a potent inhibitor of tumour-associated angiogenesis [35] . ZFP36L2 is up-regulated 69-fold by expression of E6 in untreated cells (Figure 3 C6orf32  CCGN2  CCL5  CFB  CROP  CTNNA1  ENC1  EPPK1  GJC1  HOPX  HSP90AB1   IF127  IGF1R  IL1RL1  JPH2  PDE4DIP  RBM47  SCNN1G  SERPINB13  SLC16A7  SRRM2  TAOK1  TPR  USP47  ZFP36L2 C6orf32  CCGN2  CCL5  CFB  CROP  CTNNA1  ENC1  EPPK1  GJC1  HOPX  HSP90AB1   IF127  IGF1R  IL1RL1  JPH2  PDE4DIP  RBM47  SCNN1G  SERPINB13  SLC16A7  SRRM2  TAOK1  TPR  USP47 (Figures 2  and 3A) . Following 2 days of cidofovir treatment of E6 cells, ZNF294 was reduced to undetectable levels when compared with untreated E6 cells ( Figure 5B ). Comparison of 2-day cidofovir-treated vector cells with E6 cells treated in the same way shows that ZNF294 is reduced to undetectable levels in the presence of E6 ( Figure 5B ). ZNF294 has been implicated as a tumour suppressor, as biallelic inactivating mutations have been found in this gene in colon cancers [37] .
Compared with vector cells, expression of the potential tumour suppressor HOPX [38] was reduced to undetectable levels in E6 cells (Figure 3) . Treatment of vector cells with cidofovir induced 2.2-and 101-fold increases in HOPX following 2-day and chase drug treatments, respectively ( Figure 4A ), yet this remained undetectable in E6 cells treated at the same data points ( Figure 4B ). Most significantly, low HOP expression is strongly associated with development of hypopharyngeal carcinoma [39] .
The cyclin CCGN2 down-regulates fivefold following 2 days of drug treatment in vector cells yet it drops to undetectable levels in E6 expressing cells treated in the same way. Because CCGN2 is known to be transactivated by p53 and is growth inhibitory [40] , this observation is consistent with the known ability of E6 to compromise the function of p53. The p53 dependent transactivation of CCGN is known to be part of the stress-activated damage response of cells [40] : thus, cidofovir has the potential to specifically compromise the growth inhibitory and pro-apoptotic activity of CCGN2 in E6-expressing cells.
The expression of epiplakin (EPPK1) is completely switched off by E6 (Figure 3) , it is up-regulated 437-fold following 2 days of cidofovir treatment in vector cells ( Figure 4A ) yet it remains undetectable in drugtreated E6 cells ( Figures 3B) . Functionally, EPPK1 stabilises intermediate filament networks [41] and its down regulation has been shown to enhance keratinocytre migration in vivo [42] .
Using the clonogenic assay results to guide the subsequent analysis of gene expression, our data indicates that combining expression of the low-risk HPV6b E6 protein with low-dose cidofovir can very specifically alter the expression of genes that are known to be associated with malignant conversion. Furthermore, it is surprising and significant that these effects were seen with just the E6 gene in isolation from other HPV genes, which would also undoubtedly promote oncogenic conversion (for example, E7). A recent review of published papers on cidofovir usage in RRP indicated that there is no increased risk of malignancy, although this was concluded from an accumulated total of only 188 patients over a maximum follow-up of 31 months, although the majority were for considerably shorter follow-up. Furthermore, the design of the review was to evaluate the effect of cidofovir upon the condition, rather than to specifically evaluate potential oncogenicity, which would obviously require a considerably longer follow-up period. As a consequence, this does not address the potential longer term possibility of malignant changes. Indeed, there were two patients who developed verrucous squamous cell carcinoma, although these were presumed to be the result of an inaccurate diagnosis at the outset. A recent report has suggested a link between cidofovir being injected into laryngeal lesions with the subsequent development of a squamous cell carcinoma located in the trachea [43] . Furthermore, another report comments on two cases of malignant transformation in patients receiving cidofovir from a total of 21 patients monitored over 14 years [44] . Carcinogenesis can take 20-30 years to manifest and the predicted malignant transformation rate for juvenile onset RRP<1% and 2-3% for adult onset RRP [7] . Thus, a study encompassing 188 patients most probably has insufficient power to rule out longterm carcinogenic effects of cidofovir. Work published by Carvalho et al. [45] suggested a low threshold for administering cidofovir as 91% of the patients received cidofovir. From a total of 72 patients, 9 developed dysplasia, 1 carcinoma in situ and 1 invasive carcinoma over 30 months [45] . Furthermore, others have identified a transformation rate of 2.7% in 188 patients [46] . In this study, the literature was searched for reports of patients treated with cidofovir, although the validity of this depends on the motivation of individuals to publish such cases.
A serial analysis of gene expression study has been carried out on two patients before and after cidofovir treatment [47] , although this type of analysis is complicated by genetic variation between patients, mixed cellularity and non-ideal sampling time points. Furthermore, papilloma samples were harvested before cidofovir administration and then again 2 months after cidofovir injection. No firm conclusions were drawn from this study. The advantage of our in vitro approach is that it is based upon a clean isogenic system that is more likely to reveal differences because of the presence of HPV E6 and exposure to cidofovir. Furthermore, unlike patient biopsies, the timing of sampling points for gene expression analysis can be optimized for observed differences in cell survival/ growth characteristics. The disadvantage is that it is an in vitro system, and might not accurately reflect the in vivo response. The ideal clinical evaluation would require a biopsy of the papillomatous lesions before cidofovir injection and then within 7 days following treatment. Clearly a research proposal to subject a child to repeated anaesthesia for this purpose would be unlikely to receive ethical approval.
In summary, despite the necessary limitations to our study, it is our opinion that real caution should be exercised prior to the use of cidofovir to treat RRP. Moreover, a recent double-blind randomized control trial on the effect of cidofovir on RRP has not demonstrated any clinical benefit with the use of this drug [48] . Thus it is apparent that, at the very least, more information about cidofovir should be given to the patients during the consenting process.
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